Gold prices have dropped sharply below $4,000 an ounce this year, losing 13% amid weak investor interest. However, Société Générale analysts expect a $3 billion buying surge in January due to annual index rebalancing, which will increase gold's weighting in major commodity benchmarks like the Bloomberg Commodity Index. This rebalancing is driven by a need to reduce exposure to outperforming commodities like energy and boost underperforming ones such as gold and silver. The bank also forecasts silver inflows of $2.5 billion and notes that precious metals are becoming a larger part of commodity portfolios, with gold's target weighting rising significantly by 2027. Despite recent struggles, investor interest in gold remains resilient, supported by broader commodity market growth this year.
Gold's expected $3.3 billion buying surge on index rebalancing follows a 13% price decline this year. For readers following US stocks on Pluang, here is the market snapshot as of Nov 13, 2026 02:01 WIB: breadth showed 40 stocks rose and 110 fell. Notable movers include LCID at USD 3.31 with a 1-day change of -9.81% and 100% buy order activity, PLUG at USD 1.24 down 8.49% with 78% buy orders, and NVAX at USD 9.20 down 7.82% with 99% buy orders.
BASF has agreed to sell its global mining solutions business to SNF, a specialty chemical company based in France, following a strategic review of BASF's Performance Chemicals division. The deal includes BASF's mining chemicals portfolio, production ...
TDG Gold Corp. has agreed to sell a 51% interest in its Aurora West property to Freeport-McMoRan for C$110 million in cash. Freeport also has an option to increase its ownership to 75% or 100% by funding an additional C$80 million in exploration and ...
Union Station Homeless Services is requesting community help to donate 627 frozen turkeys for its annual Dinner in the Park event, aiming to serve 6,000 Thanksgiving meals. The turkey drive will be held on November 16-17 in Pasadena, California. Dona...
Timeplast, a materials company with over 9,000 customers, has launched a Regulation A+ offering open to the public to license its patented water-soluble plastic technology. This plastic dissolves in water after a programmed period, reducing plastic w...
DelveInsight's 2026 report highlights more than 100 BCMA-targeted therapies in various clinical stages, focusing on multiple myeloma and other diseases. Leading pharma companies like Pfizer, Regeneron, and AstraZeneca are advancing treatments includi...
